Current update of adoptive immunotherapy using cytokine-induced killer cells to eliminate malignant gliomas
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Ryu, Je Il | - |
dc.contributor.author | Han, Myun Hoon | - |
dc.contributor.author | Cheong, Jin Hwan | - |
dc.contributor.author | Kim, Jae Min | - |
dc.contributor.author | Kim, Choong Hyun | - |
dc.date.accessioned | 2022-07-14T16:26:52Z | - |
dc.date.available | 2022-07-14T16:26:52Z | - |
dc.date.created | 2021-05-11 | - |
dc.date.issued | 2017-03 | - |
dc.identifier.issn | 1750-743X | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/152850 | - |
dc.description.abstract | The therapeutic outcome for those with malignant glioma is poor, even though diverse therapeutic modalities have been developed. Immunotherapy has emerged as a therapeutic approach for malignant gliomas, making it possible to selectively treat tumors while sparing normal tissue. Here, we review clinical trials of adoptive immunotherapy approaches for malignant gliomas. We also describe a clinical trial that examined the efficacy and safety of autologous cytokine-induced killer (CIK) cells along with concomitant chemoradiotherapy for newly diagnosed glioblastoma. These CIK cells identify and kill autologous tumor cells. This review focuses on the use of adoptive immunotherapy for malignant gliomas and reviews the current literature on the concept of antitumor activity mediated by CIK cells. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | FUTURE MEDICINE LTD | - |
dc.title | Current update of adoptive immunotherapy using cytokine-induced killer cells to eliminate malignant gliomas | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Ryu, Je Il | - |
dc.contributor.affiliatedAuthor | Han, Myun Hoon | - |
dc.contributor.affiliatedAuthor | Cheong, Jin Hwan | - |
dc.contributor.affiliatedAuthor | Kim, Jae Min | - |
dc.identifier.doi | 10.2217/imt-2017-0003 | - |
dc.identifier.scopusid | 2-s2.0-85016811944 | - |
dc.identifier.wosid | 000406301100005 | - |
dc.identifier.bibliographicCitation | IMMUNOTHERAPY, v.9, no.5, pp.411 - 421 | - |
dc.relation.isPartOf | IMMUNOTHERAPY | - |
dc.citation.title | IMMUNOTHERAPY | - |
dc.citation.volume | 9 | - |
dc.citation.number | 5 | - |
dc.citation.startPage | 411 | - |
dc.citation.endPage | 421 | - |
dc.type.rims | ART | - |
dc.type.docType | Review | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Immunology | - |
dc.relation.journalWebOfScienceCategory | Immunology | - |
dc.subject.keywordPlus | T-CELLS | - |
dc.subject.keywordPlus | GLIOBLASTOMA-MULTIFORME | - |
dc.subject.keywordPlus | PHASE-III | - |
dc.subject.keywordPlus | ADJUVANT IMMUNOTHERAPY | - |
dc.subject.keywordPlus | CIK CELLS | - |
dc.subject.keywordPlus | IN-VITRO | - |
dc.subject.keywordPlus | SURVIVAL | - |
dc.subject.keywordPlus | RECURRENT | - |
dc.subject.keywordPlus | EFFICACY | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordAuthor | adoptive immunotherapy | - |
dc.subject.keywordAuthor | clinical trials | - |
dc.subject.keywordAuthor | cytokine-induced killer (CIK) cells | - |
dc.subject.keywordAuthor | cytotoxicity | - |
dc.subject.keywordAuthor | glioma | - |
dc.subject.keywordAuthor | immune response | - |
dc.identifier.url | https://www.futuremedicine.com/doi/10.2217/imt-2017-0003 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.